about
In-silico human genomics with GeneCardsPositioning of Tacrolimus for the Treatment of Diabetic Nephropathy Based on Computational Network AnalysisEvaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profilesComputational analysis workflows for Omics data interpretation.Transforming omics data into context: bioinformatics on genomics and proteomics raw data.Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies.Characterization of protein-interaction networks in tumors.Linking the ovarian cancer transcriptome and immunomeHypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease.Linking transcriptomic and proteomic data on the level of protein interaction networks.Data and knowledge management in cross-Omics research projects.Molecular pathogenesis of post-transplant acute kidney injury: assessment of whole-genome mRNA and miRNA profiles.From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action.Increased renal versican expression is associated with progression of chronic kidney disease.Protein interactome of muscle invasive bladder cancer.A 3-biomarker-panel predicts renal outcome in patients with proteinuric renal diseases.Biocompatibility of peritoneal dialysis solutions determined by genomics of human leucocytes: a cross-over studyA panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes.Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancerAnalysis and prediction of protective continuous B-cell epitopes on pathogen proteins.Gene expression and biomarkers in renal transplant ischemia reperfusion injury.Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspectiveFunctional molecular units for guiding biomarker panel design.Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade.Molecular disease presentation in diabetic nephropathy.Impaired metabolism in donor kidney grafts after steroid pretreatment.Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine.Proteomic-Biostatistic Integrated Approach for Finding the Underlying Molecular Determinants of Hypertension in Human Plasma.Mass spectrometric/bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides.Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes Mellitus.Predictive Biomarkers for Linking Disease Pathology and Drug Effect.The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential.Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion.The surface properties of nanocrystalline diamond and nanoparticulate diamond powder and their suitability as cell growth support surfaces.Metallothioneins and renal ageing.Bortezomib-induced survival signals and genes in human proximal tubular cells.Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells.Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes in fatty acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease.Linking molecular feature space and disease terms for the immunosuppressive drug rapamycin.
P50
Q21245450-9D7B50C3-58AB-4E38-9A22-13C81BA6A199Q28468441-2C7FC146-72FB-4E2D-94EA-6B677FA503EAQ28484239-ACE0773B-5334-4CB6-92C6-20A2C5EEEC1AQ30484863-2ED5A919-B066-464E-8F6D-4CFFE60EFDD6Q31043070-94283659-6BF0-4C03-83B8-F402A7C140F3Q33267253-945B7409-955B-4C2B-8B10-B3C0C2666CEAQ33289133-D62DDC12-14D8-4F3E-8203-0FC3F0B94127Q33313203-B89B6F69-59E4-4CA9-9206-4BDE74856217Q33399420-9B7E83B6-FB98-403F-835E-927F06E6453CQ33568802-8996956F-8184-4124-BD54-8727C9E6E801Q33836067-75260EEC-F461-45C3-BF78-48303E0327D1Q34005059-7B121DF7-174C-4319-B248-B0E964A79C97Q34391213-2347D0EE-8703-47DB-8AED-921A3FD4476CQ34425104-7F859587-CA64-4252-8A24-146BAD2C9E77Q34876528-8F55CB56-16F1-450A-B050-B13F8EFAFCA5Q34995501-25ADE63D-0F6E-49F6-9286-C87F100318B6Q35573864-F788592C-00C7-45A8-9CCB-0E75B3DBC461Q35606905-5BBC5C40-8166-4331-9CA3-996820AD9FD4Q35992948-BC6BA272-BD62-4BB1-97D2-A55E32ABFB83Q36462613-AC20D4EB-B620-41D2-899A-6FA329296B21Q36689228-BF3D261D-163A-4E7E-863A-0025E87A13A9Q37081787-F96646F5-0445-4577-8B52-6A15A89E5911Q38208681-ECA486C0-807E-4E6C-BEC9-9AA7795E7A41Q38316361-EC9D3802-544D-417F-A31A-02B8E521A6BCQ38460161-5400ACE9-C66F-4847-9C73-AB206C1BB9C4Q38507414-2139276E-478A-44D4-AB33-D3F5123E84EEQ38553911-EBB3B85F-1026-4493-B0E1-020EDA10601DQ38707970-7ED76B15-E7D4-464C-8BF5-E10392C574CEQ38958921-9A0B8895-05E6-4B23-8278-B80CD7427023Q39026273-F7B53B55-F726-4F9F-89B0-E5EDE521C56EQ39309705-5A9A41A8-07CC-4021-AD24-D8ECA0EB65EBQ39727971-28B48F6B-8D5C-4708-8AA3-B72DB6B3659CQ39774780-181C343A-86CB-482E-B5F3-43632257498FQ39892432-B438F389-1BC9-4B22-8D73-F871E9076528Q39950990-B415ECD0-7ED5-4321-BF5E-E7CFE418D51AQ40779887-ED06E1D9-06DA-427F-9E96-CECE08EB7655Q42441352-6A5FB4F6-84AF-49CC-93CB-F2BB721E0B3AQ42459552-EB5436FA-BCEA-473E-8828-62EF3CEFEDDDQ44404635-2BEA2BC0-5554-48B7-B25A-C4B198C65A87Q44461727-FFD02A3A-6A22-4AF0-A35C-C14F52CD8CD8
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paul Perco
@ast
Paul Perco
@en
Paul Perco
@es
Paul Perco
@nl
Paul Perco
@sl
type
label
Paul Perco
@ast
Paul Perco
@en
Paul Perco
@es
Paul Perco
@nl
Paul Perco
@sl
prefLabel
Paul Perco
@ast
Paul Perco
@en
Paul Perco
@es
Paul Perco
@nl
Paul Perco
@sl
P106
P1153
6508063067
P21
P31
P496
0000-0003-2087-5691